Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

8.4K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
8.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD19 CAR T cell therapy in systemic sclerosis: A case study that reaffirms the promise of cell therapy to treat autoimmune disease.

Molecular therapy. Advances·2026
Same author

Rab5 improves CAR T cell efficacy via reducing fratricide and maintaining surface CAR levels.

The Journal of experimental medicine·2026
Same author

Antigen-boosted CD4CAR T cells fail to expand or control viremia in multiple nonhuman primate models of HIV.

Blood·2026
Same author

The ancestral haplotype of P2RX5 yields a B-cell surface marker and a multi-lineage immunotherapy target.

bioRxiv : the preprint server for biology·2026
Same author

Clinical trial results provide the rationale to protect dual HIV-specific T cells with a signaling-defective HIV fusion inhibitor.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Engineering single-vector logic-gated CAR T cells with transgene sizes beyond current limitations.

Journal for immunotherapy of cancer·2026

Related Experiment Video

Updated: Apr 14, 2026

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model
11:38

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Published on: July 2, 2016

11.1K

Engineering T Cells to Functionally Cure HIV-1 Infection.

Rachel S Leibman1, James L Riley1

  • 1Department of Microbiology and the Abramson Family Cancer Research Institute, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|April 22, 2015
PubMed
Summary

Gene editing T cells offers a promising path to a functional cure for human immunodeficiency virus type 1 (HIV-1). This approach aims to create HIV-1-resistant cells for sustained viral control without lifelong antiretroviral therapy.

More Related Videos

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

1.1K
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.9K

Related Experiment Videos

Last Updated: Apr 14, 2026

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model
11:38

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Published on: July 2, 2016

11.1K
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

1.1K
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.9K

Area of Science:

  • Immunology
  • Virology
  • Gene Therapy

Background:

  • Antiretroviral therapy (ART) manages human immunodeficiency virus type 1 (HIV-1) but necessitates lifelong treatment.
  • T cells are crucial for viral control but are also destroyed by HIV-1.
  • A permanent cure for HIV-1 is highly desirable due to treatment burdens.

Purpose of the Study:

  • To review T-cell gene-engineering and gene-editing strategies for inhibiting HIV-1 replication.
  • To highlight requirements for a successful gene therapy-mediated functional cure for HIV-1.

Main Methods:

  • Focuses on reviewing existing T-cell gene-engineering and gene-editing strategies.
  • Examines approaches to generate HIV-1-resistant cells.
  • Considers methods for redirecting HIV-1-specific immune responses.

Main Results:

  • Adoptive T-cell therapy allows for customized therapeutic T cells.
  • Engineering T cells offers a potential alternative to traditional vaccine approaches.
  • Challenges remain in achieving sustained HIV-1 control via engineered T cells without ART.

Conclusions:

  • T-cell gene therapy presents a viable strategy for a functional HIV-1 cure.
  • Further research is needed to optimize T-cell engineering for durable HIV-1 suppression.
  • Customizing T cells via gene editing could overcome limitations of current HIV-1 management.